Sugi Predict

Sugi Predict / Compounds / SCHEMBL9703855

SCHEMBL9703855

SCHEMBL9703855

Cc1cc(C(=O)O)c(Cl)nc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.53
▸ NFE2L2 Q16236 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ KDM4E B2RXH2 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ SORT1 Q99523 2/20 0.45
▸ POLB P06746 2/20 0.42
▸ GABRP O00591 2/20 0.40
▸ GABRD O14764 2/20 0.40
▸ GABRA1 P14867 2/20 0.40
▸ GABRB1 P18505 2/20 0.40
▸ GABRG2 P18507 2/20 0.40
▸ GABRB3 P28472 2/20 0.40
▸ GABRA5 P31644 2/20 0.40
▸ GABRA3 P34903 2/20 0.40
▸ GABRA2 P47869 2/20 0.40
▸ GABRB2 P47870 2/20 0.40
▸ GABRA4 P48169 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31344260 1.00 KEAP1 (0.53) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL1330488 0.86 KEAP1 (0.60) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL16616066 0.86 KEAP1 (0.55) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL19454496 0.84 SMN1; SMN2 (0.40) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL10564551 0.84 KEAP1 (0.53) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL23779711 0.84 ALDH1A1 (0.39) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL21906152 0.82 POLB (0.50) ALDH1A1SMN1; SMN2MAPK1KDM4EPOLB
SCHEMBL31042412 0.82 KEAP1 (0.52) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL3936409 0.81 KEAP1 (0.50) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1
SCHEMBL3450933 0.81 KEAP1 (0.50) KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2026-01-01 — — US disclosed
US-12234221-B2 Pyridine carboxamide compounds for inhibiting NAV1.8 LIEBER INSTITUTE, INC. (US) 2025-02-25 — — US disclosed
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2022-07-21 — — US disclosed
EP-3820866-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 — — EP disclosed
CN-112689633-A For inhibiting Nav1.8 pyridine carboxamide Compounds 利伯研究所公司 2021-04-20 — — CN disclosed
US-10626126-B2 Compounds PULMOCIDE LIMITED (GB) 2020-04-21 — — US disclosed
EP-2884978-B1 NOVEL KAPPA OPIOID LIGANDS SCRIPPS RESEARCH INST (US) 2019-07-17 — — EP disclosed
US-20190092791-A1 COMPOUNDS PULMOCIDE LIMITED (GB) 2019-03-28 — — US disclosed
US-20180099954-A1 NOVEL KAPPA OPIOID LIGANDS SCRIPPS RESEARCH INST (US) 2018-04-12 — — US disclosed
US-20180099954-A1 NOVEL KAPPA OPIOID LIGANDS SCRIPPS RESEARCH INST (US) 2018-04-12 — — US disclosed
US-20150210673-A1 NOVEL KAPPA OPIOID LIGANDS THE SCRIPPS RESEARCH INSTITUTE (US) 2015-07-30 — — US disclosed
US-20150210673-A1 NOVEL KAPPA OPIOID LIGANDS THE SCRIPPS RESEARCH INSTITUTE (US) 2015-07-30 — — US disclosed
WO-2014176144-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-10-30 — — WO disclosed
CN-102015705-B Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2013-11-13 — — CN disclosed
CN-101589025-B Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors ALMIRALL LAB 2012-05-30 — — CN disclosed
CN-102015705-A Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-04-13 — — CN disclosed
CN-101589025-A Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors ALMIRALL LAB (ES) 2009-11-25 — — CN disclosed
EP-0482481-A1 Method for the preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1992-04-29 — — EP disclosed
US-4350817-A 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1982-09-21 — — US disclosed
US-4324893-A 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1982-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210673-A1 NOVEL KAPPA OPIOID LIGANDS OPRK1, OPRD1, OPRL1 KEAP1 1342/4885NFE2L2 861/4885ALDH1A1 812/4885
US-20220227732-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN2A KEAP1 2893/4885NFE2L2 2896/4885ALDH1A1 2945/4885
US-10626126-B2 Compounds QDPR, TXNRD2, TXNRD3 KEAP1 780/4885NFE2L2 1228/4885ALDH1A1 932/4885
US-12234221-B2 Pyridine carboxamide compounds for inhibiting NAV1.8 SCN8A, SCN1A, SCN2A KEAP1 2893/4885NFE2L2 2896/4885ALDH1A1 2945/4885
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN1B KEAP1 2132/4885NFE2L2 2368/4885ALDH1A1 1730/4885
US-20190092791-A1 COMPOUNDS QDPR, TXNRD2, TXNRD3 KEAP1 780/4885NFE2L2 1228/4885ALDH1A1 932/4885
US-20180099954-A1 NOVEL KAPPA OPIOID LIGANDS OPRK1, OPRD1, OPRL1 KEAP1 1342/4885NFE2L2 861/4885ALDH1A1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.